Lv5
996 积分 2022-06-06 加入
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
3天前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
3天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
24天前
已完结
Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta‐analysis
24天前
已完结
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer
1个月前
已完结
Shifting Toward Precision Oncology in SCLC Treatment
1个月前
已完结
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
2个月前
已完结
皖公网安备34019202002308
